International Journal of Endocrinology / 2016 / Article / Tab 4

Review Article

Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials

Table 4

IVF parameters and fertilization outcomes.

RefTreatmentE2 (pg/mL)r-FSH dose (IU)Stimulation daysMII Oocyte retrievedEmbryo grade 1Biochemical pregnancy (%)Pregnancy rate (%)General findings

[25]Myo-Ins
versus
FA
2,232 ± 510
versus
2,713 ± 595
1,958 ± 695
versus
2,383 ± 578
11.4 ± 0.9
versus
12.4 ± 1.4
7.14 ± 3.49
versus
7.07 ± 3.04
8.76 ± 4.12
versus
9.37 ± 3.31
0.86 ± 0.83
versus
0.81 ± 0.83
9.1
versus
10
14.6
versus
12.9
Myo-Ins significantly reduced E2 at hCG administration, total r-FSH units, number of stimulation days, and number of VG-DEG, with a trend for increased percentage of oocytes in MII. Number of oocytes retrieved did not differ in the 2 groups.

[26]Myo-Ins
versus
FA
Reduced in
Myo-Ins group
versus
control
Reduced in
Myo-Ins group
versus
control
NA82.24%
versus
66.87%
12
versus
8.50
68.1%
versus
29%
No
differences
NAMyo-Ins has a positive effect on mature oocytes development and reduction of E2 and total r-FSH. Number of follicles with a diameter >15 mm visible at ultrasound scan during stimulation and the number of oocytes retrieved at the pick-up resulted significantly higher in the Myo-Ins-treated group. The number of immature oocytes was significantly reduced, and there was an increasing trend of the rate of oocytes in MII.

[27]Myo-Ins
versus
metformin
NA3 cycles × 37.5 U/day
(if no pregnancy occurred)
NANANANA30
versus
18.3
48.3
versus
36.6
Both Myo-Ins and metformin can be considered as first-line treatment for restoring normal menstrual cycles in most patients with PCOS; however Myo-Ins treatment seems to be more effective than metformin.

[28]D-chiro-Ins (2400 mg)
versus
placebo
1,490.24 ± 253.21
versus
1,429.69 ± 1,118.43
2,983.0 ± 219.80
versus
2,239.7 ± 181.55
13.8 ± 0.87
versus
11.4 ± 1.2
Decreased progressively after
D-chiro-Ins administration
No differencesDecreased progressively after D-chiro-Ins administrationNANAHigh D-chiro-Ins dosage negatively affects oocyte quality. It worsens oocyte quality and ovarian response in nonobese and non-insulin resistant PCOS women.

[29]Myo-Ins
versus
D-chiro-Ins
2,261.2 ± 456.6
versus
2,740 ± 396.67
1,953.6 ± 397.5
versus
2,360.5 ± 301.9
11.1 ± 0.8
versus
12.7 ± 1.1
8.21 ± 2.39
versus
7.08 ± 2.67
8.90 ± 2.84
versus
9.32 ± 3.15
1.64 ± 0.88
versus
0.76 ± 0.43
14
versus
9
51
versus
24
Myo-Ins significantly increased number of MII and decreased number of immature oocytes compared to D-chiro-Ins. Furthermore, it increased the mean number of top quality embryos and the total number of pregnancies compared to D-chiro-Ins. Number of oocytes retrieved did not differ in the two treatments groups.

[30]Myo-Ins +
D-chiro-Ins
versus
D-chiro-Ins
Age
≤35
2,230.09 ± 827.57
versus
2,537.94 ± 860.19
1,569.02 ± 497.12
versus
1,899.21 ± 618.17
NA7.91 ± 4.51
versus
8.00 ± 3.92
9.91 ± 4.85
versus
10.79 ± 4.66
0.96 ± 0.83
versus
0.73 ± 0.73
NANAThe combined treatment with Myo-Ins + D-chiro-Ins, rather than D-chiro-Ins alone, was able to improve oocyte quality and high-quality embryos in PCOS women undergoing ART regardless of the age.
Age
≥35
2,185.09 ± 409.08
versus
2,519.85 ± 788.49
1,906.96 ± 770.59
versus
2,170.58 ± 694.44
NA6.91 ± 2.26
versus
8.35 ± 5.19
8.35 ± 3.21
versus
10.75 ± 5.23
0.90 ± 0.80
versus
0.68 ± 0.80
NANA

Myo-Ins, myo-inositol; D-chiro-Ins, D-chiro-inositol; FA, folic acid; PCOS, polycystic ovary syndrome; E2, oestradiol; r-FSH, recombinant follicle stimulating hormone; MII, mature oocytes; VG-DEG, immature oocytes and degenerated oocytes; hCG, Human Chorionic Gonadotropin; ART, assisted reproductive technology.
Values are mean ± SD. Values are shown as median. A brief description is inserted in the table when numerical data are not available.
value: ≤0.05; ≤0.01; ≤0.001: comparison posttreatment experimental group versus control.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.